Delving into the Latest Updates on Zeno Alpha, Inc. with Synapse

Overview

This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in combination with abemaciclib (VERZENIO®) in participants with advanced estrogen-receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.

Start Date12 Nov 2020

Sponsor / Collaborator

Zeno Alpha, Inc.

NCT04561752 / CompletedPhase 1

A Randomized, Open-Label, 2-Way Crossover, Single-Dose Food Effect Study of ZN-c5 in Healthy Adult Post-Menopausal Female Subjects

This is a single-center, randomized, open-label, two-period, 2-way crossover food effect study to determine the comparative bioavailability of ZN-c5 under fed and fasting conditions, following single-dose administration of ZN-c5 capsules (150mg).

Start Date02 Nov 2020

Sponsor / Collaborator

Zeno Alpha, Inc.

100 Clinical Results associated with Zeno Alpha, Inc.

Login to view more data

0 Patents (Medical) associated with Zeno Alpha, Inc.

Login to view more data

100 Deals associated with Zeno Alpha, Inc.

Login to view more data

100 Translational Medicine associated with Zeno Alpha, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data